Scinai Immunotherapeutics will host a webinar on May 7 to present details about PC111, a novel monoclonal antibody with potential treatment applications for rare and challenging skin disorders. The company will discuss the antibody's mechanism for targeting soluble Fas ligand and its implications for addressing unmet medical needs in conditions like Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN).
The webinar follows Scinai's recent strategic acquisition of Pincell and a significant €12 million grant application under Poland's FENG program. Executives from both Scinai and Pincell will participate, offering insights into the development plans and potential medical significance of PC111.
This presentation represents a critical step in advancing potential treatments for rare skin disorders, which currently have limited therapeutic options. By targeting soluble Fas ligand, PC111 could offer a promising approach to managing these complex and often devastating medical conditions.
The webinar will include a live question-and-answer segment, providing an opportunity for medical professionals, researchers, and investors to gain deeper understanding of this innovative therapeutic approach.
